Tianjin Pharmaceutical Da Ren Tang Group’s Parent Lifts Stake to 43.09%

SGX Filings

08/04

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced that JinYao Global Pte. Ltd., a wholly owned unit of Tianjin Pharmaceutical Holdings Co., completed its six-month share-buy programme on Aug, 3 2026.

Between Feb, 4 2026 and the end of the plan, JinYao Global bought 724,200 S-shares on the Singapore Exchange for a total of about 2.8 million Singapore dollars, or an average of roughly USD 2.89 per share.

Following the purchases, the parent company’s stake in Tianjin Pharmaceutical Da Ren Tang Group rose to 43.09% from 42.997%, with its S-share holding increasing to 5.989 million shares from 5.265 million.

The company said the transactions complied with all relevant regulations, stayed within the announced spending cap and will not reduce the public float or alter the firm’s control structure.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1110996532"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1110996532\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1110996532?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 18:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110996532","market":"sg","top_or_hot":-1,"title":"Tianjin Pharmaceutical Da Ren Tang Group’s Parent Lifts Stake to 43.09%","media":"SGX Filings","content":"<p>Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced that JinYao Global Pte. Ltd., a wholly owned unit of Tianjin Pharmaceutical Holdings Co., completed its six-month share-buy programme on Aug, 3 2026.</p>\n<p>Between Feb, 4 2026 and the end of the plan, JinYao Global bought 724,200 S-shares on the Singapore Exchange for a total of about 2.8 million Singapore dollars, or an average of roughly USD 2.89 per share.</p>\n<p>Following the purchases, the parent company’s stake in Tianjin Pharmaceutical Da Ren Tang Group rose to 43.09% from 42.997%, with its S-share holding increasing to 5.989 million shares from 5.265 million.</p>\n<p>The company said the transactions complied with all relevant regulations, stayed within the announced spending cap and will not reduce the public float or alter the firm’s control structure.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tianjin Pharmaceutical Da Ren Tang Group’s Parent Lifts Stake to 43.09%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTianjin Pharmaceutical Da Ren Tang Group’s Parent Lifts Stake to 43.09%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1083912268\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">SGX Filings </p>\n<p class=\"h-time smaller\">2026-08-04 18:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced that JinYao Global Pte. Ltd., a wholly owned unit of Tianjin Pharmaceutical Holdings Co., completed its six-month share-buy programme on Aug, 3 2026.</p>\n<p>Between Feb, 4 2026 and the end of the plan, JinYao Global bought 724,200 S-shares on the Singapore Exchange for a total of about 2.8 million Singapore dollars, or an average of roughly USD 2.89 per share.</p>\n<p>Following the purchases, the parent company’s stake in Tianjin Pharmaceutical Da Ren Tang Group rose to 43.09% from 42.997%, with its S-share holding increasing to 5.989 million shares from 5.265 million.</p>\n<p>The company said the transactions complied with all relevant regulations, stayed within the announced spending cap and will not reduce the public float or alter the firm’s control structure.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"T14.SI","symbol_name":"達仁堂","start_time":0,"source_url":"","article_id":"1110996532","we_media_id":"1083912268","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110996532","pubTimestamp":1785838337,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"SGX Filings","introduction":"Fastest News on SGX Filings ","home_visible":1,"id":"1083912268","head_image":"https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39"},"summary":"Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced that JinYao Global Pte. Ltd., a wholly owned unit of Tianjin Pharmaceutical Holdings Co., completed its six-month share-buy...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"T14.SI":"达仁堂"},"translate_title":"天津医药大仁堂集团母公司增持股份至43.09%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"T14.SI":1},"content_text":"Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced that JinYao Global Pte. Ltd., a wholly owned unit of Tianjin Pharmaceutical Holdings Co., completed its six-month share-buy programme on Aug, 3 2026.\nBetween Feb, 4 2026 and the end of the plan, JinYao Global bought 724,200 S-shares on the Singapore Exchange for a total of about 2.8 million Singapore dollars, or an average of roughly USD 2.89 per share.\nFollowing the purchases, the parent company’s stake in Tianjin Pharmaceutical Da Ren Tang Group rose to 43.09% from 42.997%, with its S-share holding increasing to 5.989 million shares from 5.265 million.\nThe company said the transactions complied with all relevant regulations, stayed within the announced spending cap and will not reduce the public float or alter the firm’s control structure.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}